Britain’s biggest drugmaker, AstraZeneca, has set out a bold ambition to reach $80bn (£63bn) in revenues by 2030 from treatments for cancer, rare diseases and other conditions, by launching 20 major new medicines before the end of the decade. As the company prepared to present its growth plans to shareholders at its labs and corporate headquarters in Cambridge, it said many of the 20 new drugs will have the potential to generate more than $5bn in annual revenues at their peak. The Anglo-Swedish pharmaceutical company made revenues of $45.8bn last year, achieving the goal it had set out as part of its defence against a £70bn hostile takeover approach from US rival Pfizer in 2014 one year early. Related: UK grocery inflation lowest since October 2021; Mastercard and Visa face ‘no effective competition’ – business live “Today AstraZeneca announces a new era of growth,” the chief executive, Pascal Soriot, said. “The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade.” The company said it would continue to invest in “transformative new technologies and platforms that will shape the future of medicine”. With Soriot at the helm, AstraZeneca has revamped...